Mourouzis, Iordanis S.
Lourbopoulos, Athanasios I.
Trikas, Athanasios G.
Tseti, Ioulia K.
Pantos, Constantinos I. http://orcid.org/0000-0003-2449-0991
Funding for this research was provided by:
Uni-Pharma Pharmaceutical Company
Article History
Received: 18 January 2021
Accepted: 11 March 2021
First Online: 9 April 2021
Declarations
:
: The protocol was approved by the Institutional Animal Care and Use Committee of Medical School, National and Kapodistrian University of Athens. All animal experiments conformed to the revised Institute of Laboratory Animal Resources, Commission on Life Sciences, National Research Council "Guide for the Care and Use of Laboratory Animals" National Academy Press, Washington, D.C. 1996.
: The work described has not been published before and is not under consideration for publication anywhere else. The submitted work is original and has been approved for publication by all co-authors.
: The following pending patents are relevant to the work in this manuscript. PCT/EP2019/087056. L-triiodothyronine (T3) for use in limiting microvascular obstruction. Greek Patent Office, number of case: 22-0002577373. Composition comprising L-triiodothyronine (T3) for use in the treatment of critically ill patients with coronavirus infection. Greek Patent Office, number of case 22-0003823965. Composition comprising L-triiodothyronine (T3) for use in the treatment of tissue hypoxia. IT, managing director of Uni-Pharma, is the sponsor of these patents. CP and IM are the inventors and hold royalties in relation to these patents.